Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

16.23
-0.1000-0.61%
Post-market: 16.230.00000.00%19:10 EDT
Volume:325.68K
Turnover:5.27M
Market Cap:468.60M
PE:-87.98
High:16.34
Open:16.32
Low:16.01
Close:16.33
Loading ...

Castle Biosciences Inc. to Present at Canaccord Genuity 45th Annual Growth Conference

Reuters
·
Yesterday

BRIEF-Castle Biosciences’ Founder, President And CEO Derek Maetzold Named A Most Admired CEO By The Houston Business Journal

Reuters
·
25 Jul

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

THOMSON REUTERS
·
25 Jul

Castle Biosciences' DecisionDx-Melanoma Test Receives FDA Breakthrough Device Designation

Reuters
·
23 Jul

Castle Biosciences Inc. to Release Second Quarter 2025 Financial Results

Reuters
·
14 Jul

Derek J. Maetzold, President & CEO, Reports Disposal of Common Shares in Castle Biosciences Inc

Reuters
·
02 Jul

BRIEF-Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
19 Jun

Castle Biosciences Announces Inducement Grants with RSUs for 66 New Employees Under 2022 Plan

Reuters
·
19 Jun

Lake Street Reaffirms Their Buy Rating on Castle Biosciences (CSTL)

TIPRANKS
·
17 Jun

Castle Biosciences enters collaboration, license agreement with SciBase

TIPRANKS
·
17 Jun

Castle Biosciences Inc. Announces Collaboration with SciBase for Development of Diagnostic Test Predicting Atopic Dermatitis Flares

Reuters
·
17 Jun

Castle Biosciences CEO Derek Maetzold to Participate in Panel Discussion at 2025 BIO International Convention

Reuters
·
11 Jun

Castle Biosciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
24 May

Castle Biosciences Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
21 May

Castle Biosciences price target lowered to $40 from $44 at Scotiabank

TIPRANKS
·
21 May

Castle Biosciences Inc. to Present at the 2025 Jefferies Global Healthcare Conference

Reuters
·
21 May

U.S. RESEARCH ROUNDUP-Levi Strauss, Myriad Genetics, Palo Alto

Reuters
·
21 May

Castle Biosciences Is Maintained at Buy by Lake Street

Dow Jones
·
07 May

Stock Track | Castle Biosciences (CSTL) Plummets 14.21% as Q1 Earnings Fall Short of Expectations

Stock Track
·
06 May

Castle Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
06 May